Evaluation of Tolerance and Acceptability of a Coated Condom
NCT ID: NCT01619397
Last Updated: 2017-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2012-09-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Investigation to Assess the Performance of Natural Rubber Latex Condoms in Couples
NCT03739190
A Clinical Investigation to Assess the Performance of a Polyurethane Condom Versus a Latex Condom in Healthy Monogamous Couples
NCT04134039
A 3-way Crossover Clinical Investigation to Assess the Performance of Two Different Sized Polyurethane Condoms Versus a Latex Condom in Healthy Monogamous Couples.
NCT06557499
A 24 Hour Occlusive Single Patch Test to Assess Acute Tolerance of Pre Lubricated Condom on a Panel of Healthy Adult Subjects
NCT02864966
Evaluation of the Performance and Acceptability of a Synthetic Polyisoprene Male Condom Compared to a Natural Rubber Latex Condom
NCT06595836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Condoms are a widely used, cheap and effective contraceptive and an important primary prevention strategy that can substantially reduce the likelihood of transmitting sexually transmitted infections (STI's) (Holmes et al, 2004). Consumer studies have revealed that the 'messiness' associated with pre lubricated condoms can be off putting to the consumer and possibly deter use completely. It is thought that as the condom coating is initially dry to the touch this may remove the 'messiness'.
The duration of the Investigation is 3 days. In that time subjects will attend the clinic 3 times, (Day 1, Day 2 and Day 3) for baseline assessments and subsequent Clinical Assessments. Clinical Assessments will include an examination of the external genitals (both male and female subjects) and internal genitals (female subjects only) in order to make an assessment of dermal tolerance of the area when exposed to a Project Unusual Condom in-use.
Couples will be provided with Investigation Device at visit 1 and Visit 2. There is a 24 hour period after receipt of Investigational Device in which couples are asked to use the condom for 1 act of vaginal intercourse, recording compliance and their experience of the Investigational Device in a Diary Card and questionnaire.
Assessments of tolerance will be made by the PI throughout the Investigation. The PI is a Physician with extensive Dermatology training. Assessments of dermal tolerance will include scoring particular sites according to a Total Irritancy score, providing a Global Assessment of Tolerance and at the end of the Clinical Investigation the Investigator will make an Overall Tolerance Rating Statement.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Condom
Test condom with new Xanthan gum condom coating
Test condom with new Xanthan gum condom coating
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test condom with new Xanthan gum condom coating
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects at least 18 years of age
* Subjects who are willing and able to take part, attend all required visits, able to understand the information given to them and give written consent
* Couples who are be experienced latex condom users as defined by repeated use without significant problems.
* Couples must agree to use the condoms provided plus be using one other acceptable form of non barrier contraception (i.e. sterilisation/vasectomy, intra-uterine device (IUD) or intra-uterine system (IUS), hormonal contraception) unless female partner is post-menopausal (i.e. over 50 and, prior to screening, amenorrhea for at least 12 months after cessation of exogenous hormone treatment) in which case no second form of contraception is required.
* No signs of abnormalities in the medical history that the investigator would consider as clinically relevant.
* No clinically relevant findings in physical assessments
* Subject not aware of any reason why they will not be able to engage in 1 act of vaginal intercourse per Condon Use Period.
Exclusion Criteria
* Pre-existing skin or systemic allergic reaction or severe eczema
* Previous history of frequent problems associated with the use of condoms
* Currently active or a history of recurrent STI's including HIV infection in one or either partner.
* Participation in a clinical trial in the previous month which could, in the opinion of the investigator, affect the outcome of the Investigation.
* Intentions to continue use of concurrent vaginal lubricants or treatments for the duration of the Investigation.
* Either partner with genital piercing
* Female partners who are pregnant or breast feeding
* Female partners seeking to become pregnant in the duration of the Investigation
* Female partner who has been diagnosed with or treated for a vaginal complaint in the previous 3 months which in the Investigators opinion indicated the partner is unsuitable for the Investigation
* Female partner suffering from known vaginal dryness
* Female partner using medication which would affect vaginal mucosal secretion, such as Chlorpheniramine.
* Male partners using medication that would affect ability to obtain and maintain an erection through to normal ejaculation
* Male partners with abnormal penile anatomy that would affect ability to keep condom in place during intercourse
* Males partner with diagnosis of penile skin condition within previous 3 months (e.g. conditions associated with balanoposthitis: penile psoriasis; lichen sclerosis; eczema) as confirmed by subject and by genital examination.
* Intentions to continue to use antihistamines, anti inflammatory drugs, or pain killers for the duration of the Investigation
* Suffering from any condition which could, in the opinion of the Investigator, affect the outcome of the Investigation
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Reckitt Benckiser LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alba Science Ltd, 24 Brought Street
Edinburgh, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPD 684_03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.